In glioblastoma treatment, ginsenoside Rg3 inhibited O6-methylguanine-DNA-methyltransferase (MGMT) by regulating the Wnt/β-catenin pathway and significantly enhanced the sensitivity of glioma to TMZ chemotherapy. This evidence concerns the gene MGMT and central nervous system cancer.